Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.

Inflamed colon that lost the capacity to undergo autophagy in the adipose tissue.
Pericardial fat associated lymphoid clusters. In green are adipocytes and in red B cells.

A fraction of inflammatory bowel disease (IBD) patients, predominantly those with Crohn's disease, develop a phenomenon known as creeping fat tissue over the course of their condition. This describes the wrapping of fat around the inflamed part of the intestine. Its biological function, whether beneficial or maladaptive however, remains unclear.

Recent results, published in The EMBO Journal, have revealed a novel crosstalk between fat tissues and the intestine suggesting that fat tissues, at least initially, may have a protective and beneficial effect by preventing excessive intestinal inflammation.

Lead author Felix Richter said: "We were interested to study the crosstalk between fat tissues and the intestine during intestinal inflammation. We focussed our efforts on the role of autophagy, a recycling pathway for cell components, in fat cells and how this would influence the inflammatory processes during colitis. Mutations or disruption of genes in the autophagy pathway have been previously associated with higher susceptibility to IBD, and Crohn's."

The study showed that intestinal inflammation induces autophagic flux in adipose tissues of mice and creeping fat of Crohn's disease patients. It identified that fat tissues increase the secretion of the anti-inflammatory cytokine IL-10 during intestinal inflammation. However, a genetic deletion of the autophagy pathway prevented this additional adipose tissue-derived IL-10 secretion, and led to more severe intestinal inflammation.

"We found that autophagy seems to be an important modulator of adipose tissue homeostasis by controlling the production of important signalling lipids which regulate the production of IL-10 from adipose tissue macrophages during intestinal inflammation," said Katja Simon, Professor of Immunology at the Kennedy Institute and MDC Berlin "The role of these signalling lipids is being investigated as possible therapeutics for IBD patients and our study adds to their possible beneficial effects."

"This was a fantastic cross-disciplinary and international research effort and wouldn't have been possible without all participating collaborators, and funding by Wellcome and Kenneth Rainin foundation," said Felix.

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.